Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase – Still a Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) shares saw unusually-high trading volume on Wednesday . Approximately 3,050,342 shares traded hands during trading, an increase of 39% from the previous session’s volume of 2,196,948 shares.The stock last traded at $39.8050 and had previously closed at $39.72.

Centessa Pharmaceuticals News Summary

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly acquisition reported — Multiple outlets report Eli Lilly will acquire Centessa in a deal worth up to $7.8B; press coverage notes shareholders would receive roughly $38 in cash plus contingent value rights tied to potential upside, which sets a clear takeover premium/floor under the stock. LLY to Buy Centessa — Zacks
• Positive Sentiment: Large call buying — Reports show unusually high volume of call-option purchases, a bullish signal from derivatives traders that may reflect takeover-related arbitrage or speculative upside interest. Investors Purchase Calls — American Banking News
• Neutral Sentiment: Guggenheim reaffirmed “neutral” — Guggenheim left its rating unchanged, signaling no strong analyst upgrade in response to the takeover buzz. Guggenheim Reaffirms — TickerReport
• Neutral Sentiment: Leerink moved to “hold” but raised price target to $40 — A mixed note: downgrading the rating but nudging the target slightly above current market levels, reflecting uncertainty about deal dynamics or timing. Leerink Downgrade / PT — Benzinga
• Negative Sentiment: Multiple analyst downgrades — Several firms (B. Riley, Lifesci Capital, Wolfe Research, Needham, Stephens and others) cut ratings to hold from stronger stances, pressuring sentiment despite the takeover reports. Analyst Downgrades — Zacks Wolfe Research — American Banking News Needham — American Banking News
• Negative Sentiment: Shareholder investigations and class-action alerts — Two law firms announced probes into the proposed sale process and price adequacy, creating legal/transaction risk that can weigh on the stock and complicate closing. Monteverde & Associates — PR Newswire KSF Investigation — BusinessWire
• Negative Sentiment: Earnings miss — Centessa reported Q (EPS -$0.48) that missed consensus (~ -$0.38), an operational disappointment that adds near-term pressure independent of M&A news. Earnings Release — MarketBeat
• Negative Sentiment: Heavy put buying — Separately, unusual volume in put options (10,659 puts, a large jump vs. average) shows some participants betting on downside or using puts for hedging around the deal. (No direct link provided in feed.)

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Finally, Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $40.00.

Centessa Pharmaceuticals Trading Down 0.4%

The firm has a market capitalization of $5.80 billion, a P/E ratio of -21.69 and a beta of 1.25. The business’s 50 day moving average is $26.93 and its two-hundred day moving average is $25.45. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). Analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the sale, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 349,073 shares of company stock worth $9,429,412 over the last quarter. 7.09% of the stock is currently owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. lifted its holdings in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares during the last quarter. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.